China Nuokang Bio-Pharmaceutical Stock Price, News & Analysis (NASDAQ:NKBP)

$5.54 0.00 (0.00 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$5.54
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market Capitalization$108.95 million
P/E Ratio-19.79
Dividend YieldN/A
BetaN/A

About China Nuokang Bio-Pharmaceutical (NASDAQ:NKBP)

China Nuokang Bio-Pharmaceutical Inc. is a biopharmaceutical company focused on research, development, manufacture, marketing and sales of hospital-based medical products. As of December 31, 2010, it sold a portfolio of 15 products, including four principal products: Baquting, its bleeding control product; Kaitong, its lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; Aiduo, its cardiovascular stress imaging agent, and Aiwen, its anti-arrhythmic agent. Its product pipeline includes three product candidates under development for bleeding control and hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. In February 2013, it announced the completion of the merger with Kingbird Mergerco. Inc., a wholly owned subsidiary of Kingbird Investment Inc. As a result of the merger the Company became a wholly owned subsidiary of Kingbird Investment Inc.

Receive NKBP News and Ratings via Email

Sign-up to receive the latest news and ratings for NKBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:NKBP
CUSIPN/A
Phone+86-24-24696033

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-19.7857142857143
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

China Nuokang Bio-Pharmaceutical (NASDAQ:NKBP) Frequently Asked Questions

What is China Nuokang Bio-Pharmaceutical's stock symbol?

China Nuokang Bio-Pharmaceutical trades on the NASDAQ under the ticker symbol "NKBP."

Who are some of China Nuokang Bio-Pharmaceutical's key competitors?

How do I buy China Nuokang Bio-Pharmaceutical stock?

Shares of China Nuokang Bio-Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is China Nuokang Bio-Pharmaceutical's stock price today?

One share of China Nuokang Bio-Pharmaceutical stock can currently be purchased for approximately $5.54.

How big of a company is China Nuokang Bio-Pharmaceutical?

China Nuokang Bio-Pharmaceutical has a market capitalization of $108.95 million.

How can I contact China Nuokang Bio-Pharmaceutical?

China Nuokang Bio-Pharmaceutical's mailing address is No. 18-1 East Nanping Road Hunnan Natnl New & High-tch Dvlpmnt Zone, SHENYANG, LIA 110171, China. The biopharmaceutical company can be reached via phone at +86-24-24696033.


MarketBeat Community Rating for China Nuokang Bio-Pharmaceutical (NKBP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about China Nuokang Bio-Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

China Nuokang Bio-Pharmaceutical (NASDAQ:NKBP) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

China Nuokang Bio-Pharmaceutical (NASDAQ:NKBP) Earnings History and Estimates Chart

Earnings by Quarter for China Nuokang Bio-Pharmaceutical (NASDAQ:NKBP)

China Nuokang Bio-Pharmaceutical (NASDAQ NKBP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/25/2012Q3 2012$0.06$0.10ViewN/AView Earnings Details
8/22/2012Q2 2012$0.07$0.09ViewN/AView Earnings Details
5/23/2012Q1 2012$0.01ViewN/AView Earnings Details
3/14/2012Q4 2011($0.07)($0.09)ViewN/AView Earnings Details
11/17/2011Q3 2011$0.07$0.06ViewN/AView Earnings Details
8/25/2011$0.11$0.11ViewN/AView Earnings Details
5/25/2011Q1 2011$0.05$0.08ViewN/AView Earnings Details
3/16/2011$0.06$0.01ViewN/AView Earnings Details
11/17/2010Q3 2010$0.11$0.07ViewN/AView Earnings Details
8/25/2010Q2 2010$0.16$0.14ViewN/AView Earnings Details
6/2/2010Q1 2010$0.07$0.13ViewN/AView Earnings Details
3/16/2010Q4 2009$0.16$0.21ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

China Nuokang Bio-Pharmaceutical (NASDAQ:NKBP) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for China Nuokang Bio-Pharmaceutical (NASDAQ:NKBP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for China Nuokang Bio-Pharmaceutical (NASDAQ NKBP)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

China Nuokang Bio-Pharmaceutical (NASDAQ NKBP) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

China Nuokang Bio-Pharmaceutical (NASDAQ:NKBP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

China Nuokang Bio-Pharmaceutical (NASDAQ:NKBP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

China Nuokang Bio-Pharmaceutical (NASDAQ NKBP) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.